Abstract
Malaria remains the most serious parasitic diseases affecting humans in the world today, resulting in 1-2 million fatalities each year. Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) are the predominant causative agents. Both are responsible for widespread mortality and morbidity and are a serious socio-economic burden, especially for countries in the developing world. One of the most important defences against malaria has been the use of chemotherapeutic drugs (e.g. chloroquine, artemisinins, pyrimethamine) but these have mainly been found by serendipity. Their mechanisms was not understood at the time of their discovery and, even today, are still not unequivocal. For many of these compounds, the parasite is now resistant and, hence, there is an urgent need to develop new therapeutic drugs directed to validated targets. One metabolic pathway crucial for the survival and replication and survival of the parasite is the synthesis of the purine nucleoside monophosphates essential for the production of DNA/RNA molecules. A key enzyme in this pathway is the 6-oxopurine phosphoribosyltransferase (PRTase). The focus of this review is on the identification and characterization of inhibitors of the enzymes from both Pf and Pv as antimalarial drug leads. The acyclic nucleoside phosphonates (ANPs) appear to be excellent candidates because they are good inhibitors of the two Plasmodium enzymes, can be selective compared to the human enzyme, can arrest parasitemia in cell based assays, have low cytotoxicity to the human host cell and, because of their stable carbon-phosphorous bond, are stable within the cell.
Keywords: Malaria, acyclic nucleoside phosphonates, hypoxanthine guanine phosphoribosyl transferase, serendipity, resistant, purine nucleoside monophosphates, ANPs, cell based assays, low cytotoxicity, carbon-phosphorous bond
Current Topics in Medicinal Chemistry
Title: 6-Oxopurine Phosphoribosyltransferase: A Target for the Development of Antimalarial Drugs
Volume: 11 Issue: 16
Author(s): John de Jersey, Antonin Holy, Dana Hockova, Lieve Naesens, Dianne T. Keough and Luke W. Guddat
Affiliation:
Keywords: Malaria, acyclic nucleoside phosphonates, hypoxanthine guanine phosphoribosyl transferase, serendipity, resistant, purine nucleoside monophosphates, ANPs, cell based assays, low cytotoxicity, carbon-phosphorous bond
Abstract: Malaria remains the most serious parasitic diseases affecting humans in the world today, resulting in 1-2 million fatalities each year. Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) are the predominant causative agents. Both are responsible for widespread mortality and morbidity and are a serious socio-economic burden, especially for countries in the developing world. One of the most important defences against malaria has been the use of chemotherapeutic drugs (e.g. chloroquine, artemisinins, pyrimethamine) but these have mainly been found by serendipity. Their mechanisms was not understood at the time of their discovery and, even today, are still not unequivocal. For many of these compounds, the parasite is now resistant and, hence, there is an urgent need to develop new therapeutic drugs directed to validated targets. One metabolic pathway crucial for the survival and replication and survival of the parasite is the synthesis of the purine nucleoside monophosphates essential for the production of DNA/RNA molecules. A key enzyme in this pathway is the 6-oxopurine phosphoribosyltransferase (PRTase). The focus of this review is on the identification and characterization of inhibitors of the enzymes from both Pf and Pv as antimalarial drug leads. The acyclic nucleoside phosphonates (ANPs) appear to be excellent candidates because they are good inhibitors of the two Plasmodium enzymes, can be selective compared to the human enzyme, can arrest parasitemia in cell based assays, have low cytotoxicity to the human host cell and, because of their stable carbon-phosphorous bond, are stable within the cell.
Export Options
About this article
Cite this article as:
de Jersey John, Holy Antonin, Hockova Dana, Naesens Lieve, T. Keough Dianne and W. Guddat Luke, 6-Oxopurine Phosphoribosyltransferase: A Target for the Development of Antimalarial Drugs, Current Topics in Medicinal Chemistry 2011; 11 (16) . https://dx.doi.org/10.2174/156802611796575911
DOI https://dx.doi.org/10.2174/156802611796575911 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advancement and Technological Aspects of Pulsatile Drug Delivery System - A Laconic Review
Current Drug Targets Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Liver and Pancreatic Disease in Cystic Fibrosis: Clinics and Drug Therapy
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Prodrug Design of Phenolic Drugs
Current Pharmaceutical Design Behavior of EDTMP (Ethylene-diaminetetramethylene-phosphonate)- Nanoparticles in Blood: Considerations on the Site of Injection
Current Nanoscience Xenobiotic Sulphation and its Variability During Inflammation: a Factor in Adverse Drug Reactions?
Current Drug Metabolism Targeted Therapy in Advanced Gastric Carcinoma: The Future is Beginning
Current Medicinal Chemistry Patent Selections
Recent Patents on Medical Imaging Ontogeny of Human Conjugating Enzymes
Drug Metabolism Letters EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Current Drug Targets Functional Poly(ε-caprolactone) Based Materials: Preparation, Self-assembly and Application in Drug Delivery
Current Topics in Medicinal Chemistry Novel Strategies and Model Studies for Colon Targeted Drug Delivery
Drug Delivery Letters Molecular Mechanisms of Epithelial Regeneration and Neovascularization During Healing of Gastric and Esophageal Ulcers
Current Medicinal Chemistry Spectral Imaging Technology - A Review on Skin and Endoscopy Applications
Recent Patents on Medical Imaging Acetaminophen (Paracetamol) and Injury in the Cardiovascular System
Vascular Disease Prevention (Discontinued) Meal Replacement Beverage Twice a Day in Overweight and Obese Adults (MDRC2012-001)
Current Nutrition & Food Science Medical Implications of Benzimidazole Derivatives as Drugs Designed for Targeting DNA and DNA Associated Processes
Current Medicinal Chemistry